Once-monthly subcutaneous olanzapine LAI requires no loading doses, oral supplementation, or post-injection monitoring, based on phase 3 SOLARIS data.
|Slideshows|September 14, 2016
ADHD Research Update: September 2016
Author(s)Mark L. Fuerst
Three new studies in children with ADHD reveal an association with seizures, the benefits of after-school exercise, and brain changes linked to treatment.
Advertisement
References:
1. Bertelsen EN, Larsen JT, Petersen L, et al.
2. Bustamante EE, Davis CL, Frazier SL, et al.
3. Schrantee A, Tamminga HGH, Bouziane C, et al.
Advertisement
Related to this article
Routine symptom measures sharpen psychiatric diagnosis, speed remission, flag relapse risk, and turn EHR data into a learning system for better care.
Once-monthly subcutaneous olanzapine TEV-749 shows sustained stabilization and remission in schizophrenia, supports direct switching, and avoids post-injection monitoring.
Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
Veterans younger than 30 starting antidepressants, and anyone coprescribed opioids and benzodiazepines, will need to sign consent forms starting in 2027.
Check out our pipeline updates from September!
A cross-sector ACNP task force calls for shared standards and shared data to move psychiatry beyond trial-and-error prescribing.
Despite previous failure of PDE10A inhibitor drugs to demonstrate antipsychotic effects in clinical trials, a new "improved" iteration has met phase 2 trial endpoints.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Olanzapine LAI (Weltruza) Receives FDA Approval for Schizophrenia
2
FDA Grants Clearance to Motivista, the First Authorized Treatment for Negative Symptoms of Schizophrenia
3
Moving Away From Treatment-Resistant Depression and Toward Difficult-to-Treat Depression
4
Blood-Based Biomarkers for Alzheimer Disease: Accuracy, Limits, and Confounders
5